Skip to main content

Medco, Mayo to Study Pharmacoeconomics of Genetically Testing Warfarin Patients

NEW YORK (GenomeWeb News) — Pharmacy benefits management company Medco and Mayo Collaborative Services plan to study whether using genetic tests can cut costs and improve care for patients taking the blood-thinner warfarin, Medco today.
 
Medco said it will work with Mayo to evaluate test data from more than 1,000 subjects from the roughly 200,000 individuals Medco tracks every year who are new to warfarin treatment.
 
The genetic testing will be performed by the Mayo Clinic’s department of laboratory medicine and pathology, and the results will be forwarded to physicians to help them determine correct drug dosage, Medco said.
 
The study will follow patients “through the normal course of treatment” and will be completed at the end of 2007. Medco said the study is the first in a line of similar collaborations that will explore the financial and health benefits of genetic tests used with other drugs.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.